Abstract

Nowadays chronic kidney disease (CKD) is one of the leading chronic non-communicable diseases in terms of morbidity and mortality. One of the most serious complications is mineral-bone disorder, which worsen the clinical course and prognosis of patients. Fibroblast growth factor 23 (FGF-23) is a new biomarker that regulates phosphate metabolism and plays an important role in the pathogenesis of many complications in CKD. Purpose. To study the physiological role of FGF-23, as well as its potential clinical significance in the progression of CKD and its complications. Material and methods. A 20-year-deep literature search was conducted in the international scientific databases PubMed / Medline, Web of Science and Google Scholar for the following keywords: "Fibroblast growth factor 23", "FGF-23", "phosphate homeostasis", "chronic kidney disease", "Mineral and bone disorders", "left ventricular hypertrophy". Results and discussion. FGF-23 is a protein secreted by bone cells and its primary physiological role is to regulate urinary excretion of phosphate to maintain a stable level in serum. Moreover, FGF-23 decreases calcitriol levels and inhibits parathyroid hormone secretion. In CKD, there is a gradual increase in FGF-23 levels as renal function declines, which can be regarded as physiological compensation to stabilize serum phosphate levels. According to the several studies, FGF-23 might be associated with cardiovascular complications, such as left ventricular hypertrophy and heart failure. Conclusion. Thus, FGF-23 is not only a marker of mineral-bone disorders in CKD, but also a key link in the pathogenesis of the development of secondary hyperparathyroidism and cardiovascular complications. With this in mind, FGF-23 may represent a multifunctional therapeutic target that may improve the prognosis of patients with CKD. Keywords: fibroblast growth factor-23, phosphate, parathyroid hormone, left ventricular hypertrophy, mineral-bone disorder.

Highlights

  • A 20-year-deep literature search was conducted in the international scientific databases PubMed / Medline, Web of Science and Google Scholar for the following keywords: "Fibroblast growth factor 23", "FGF-23", "phosphate homeostasis", "chronic kidney disease", "Mineral and bone disorders", "left ventricular hypertrophy"

  • FGF-23 is a protein secreted by bone cells and its primary physiological role is to regulate urinary excretion of phosphate to maintain a stable level in serum

  • In chronic kidney disease (CKD), there is a gradual increase in FGF-23 levels as renal function declines, which can be regarded as physiological compensation to stabilize serum phosphate levels

Read more

Summary

ОБОЩБЕЗСОТРВЫЕННОЕ ЗДРАВООХРАНЕНИЕ

14 Балабанова Р.М., ЭрдғеыслШым.Фи.мРәалсіпмреотсттерранбеанзнаолсатрьынд2а02107.жPы.л3б5о-9й.ыAтvеaрilеaңbдleетfіrлoгmен: әhдttеpб:/и/wзwерwт.тmеуzл.gеoрv.іkздz/еsнitісesі /жүрревматических заболеванийгізвілРдоі.сІсзидиеувү2ш0ін12к-е2л0е1с3і тгегр. м//индеdрefқaоuлltд/fiаlнeыs/лpдagыe:s«/s2b3oфrnиikб_р2о0б1л7а_сттардың өсу факторы», «FGF-. 14 Балабанова Р.М., ЭрдғеыслШым.Фи.мРәалсіпмреотсттерранбеанзнаолсатрьынд2а02107.жPы.л3б5о-9й.ыAтvеaрilеaңbдleетfіrлoгmен: әhдttеpб:/и/wзwерwт.тmеуzл.gеoрv.іkздz/еsнitісesі /жүрревматических заболеванийгізвілРдоі.сІсзидиеувү2ш0ін12к-е2л0е1с3і тгегр. Сонымен қgаoтаdр–, F2G01F6-2g3g.ка[Fлoьrцmит1р2и.оRл eдpеoңrtгеoйnінthтeөмnuеmндbеeтrеoдfі dжisәeнaеseпsаратиреоид гормонының секрециясыreнgiтsеteжreеdйдinі. TСhБe Аseкrvеiзcінeдaеreбaүoйfрtеhкeфmуeнdкiцcaиlясoыrgнaыniңzaтtөioмnенanдdеуіне байланысты FGF-23 деңгейінің бthірeтcінoдnеtiпngөeсnуtsі oбfаpйaқtаieлnаtдs ыw,hoонaыre uсnаdрeыrсdуiдspаeғnыsaфryоoсbфsоerрvaдtеioңnгейін тұрақтандыру үшін физиологиял2ы0қ1ө2т–ем2а0қ1ы6]д. ЕMпoсsаcнoаwу;ғаMбEоDлIаnдfoыr.mӘ.рAтvүaрilлaіbзleерfrтoтmеу:лhеtрtpге://сәйкес, FGF-23 сол жақ қарыншаныңwгwипwе.рmтeрdоiфnfиoя.kсzы және жүрек жеткіліксіздігі сияқты жүрек-қантамырлық асқынулармен байланыст1ы1бNолaуsыonмoүvмкEінL., editor. Nowadays chronic kidney disease (CKD) is one of the leading chronic non-communicable diseases in terms of morbidity and mortality. One of the most serious complications is mineral-bone disorder, which worsen the clinical course and prognosis of patients. Fibroblast growth factor 23 (FGF-23) is a new biomarker that regulates phosphate metabolism and plays an important role in the pathogenesis of many complications in CKD. To study the physiological role of FGF-23, as well as its potential clinical significance in the progression of CKD and its complications

Material and methods
Results and discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call